Salerno Named to Pierian Biosciences Board of Directors

Former CEO of Susan G. Komen Brings Health Policy, Operational Expertise to Board Leadership NASHVILLE, Tenn., April 18, 2017 – Pierian Biosciences, the premier developer of life science technologies providing treatment-directing data to aid physicians in selecting...

Immunotherapy Making Strides at ASCO-SITC Immuno-Oncology Symposium

In late February, the American Society of Clinical Oncology (ASCO) partnered with the Society for Immunotherapy of Cancer (SITC) to host the first ASCO-SITC Clinical Immuno-Oncology Symposium, held in Orlando. We learned, along with 1000 other attendees, about the...

Response to FiercePharma Article

CLIENT: Pierian Biosciences DATE: February 17, 2017 PROJECT: PR – Blog post – Response to FiercePharma article Author: Robert Henry A recent FiercePharma article on the top 15 cancer drugs for 2022 predicts they will total nearly $90 billion in sales. That’s a...

Pierian Biosciences Names Mark S. Gelder, MD as Chief Medical Officer

Oncology Professor to Guide Clinical Studies Pierian Biosciences, the premier developer of life science technologies providing treatment directing data to aid physicians in selecting the most appropriate therapy for their patients with cancer, has named Mark S....

PR – Op-Ed: Response to New Clinical Trials Requirements from HHS

Client: DiaTech Holdings/Pierian Biosciences, Inc. Date: September 21, 2016 Project: PR – Op-Ed: Response to New Clinical Trials Requirements from HHS Cancer deaths have declined substantially in the past decade. According to the National Cancer Institute, from 2003...